WVE: Wave Life Sciences Corp Kompaniya qiymatining sof foydaga nisbati
Wave Life Sciences (WVE) GSK bilan strategik ittifoq orqali o'z operatsion xarajatlarini optimallashtirmoqda, bu esa tadqiqot va ishlanmalar (R&D) xarajatlarini qoplaydi. Kompaniyaga tegishli P/E koeffitsiyenti tarixi aktivning baholash dinamikasini namoyish etadi, bunda joriy parametr -3.20 ga tengdir. Kam uchraydigan kasalliklar terapiyalariga bo'lgan talab makrotsikllardan mustaqil qolmoqda, PRISM platformasining noyob imkoniyatlari esa ilgari erishib bo'lmagan genetik maqsadlarni aniqlash imkonini beradi.
%20Narxning%20foydaga%20nisbati&width=1200&height=400&colorIndex=0&v=mwczyyub.rjb-7czcsu8&start=20220704&end=20261112&filename=GURU_Markets_-_WVE_-_Wave-Life-Sciences_-_Price-to-Earnings-Ratio "Wave Pharma (WVE): Narxning foydaga nisbati 04.07.2022dan 12.11.2026gacha | 👁️GURU.Markets👁️")
Wave Life Sciences Corp (WVE) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- bozor narxi va tahlilchilarning maqsadli narxlari:
- bozor kapitallashuvi haqida ma'lumot:
- buxgalteriya balansi bo'yicha sof aktivlar qiymati ko'rsatkichlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Jamlagan qarzning xususiy kapitalga nisbati Wave Life Sciences|WVE - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli majburiyatlarning kapitalga nisbati Wave Pharma|WVE - Kompaniyaning umumiy qarzi|Qarzning sof aktivlarga nisbati Wave Life Sciences Ltd.|WVE - Kompaniyaning uzoq muddatli qarzi|Qisqa muddatli qarz hajmi Wave Life Sciences|Tezkor likvidlik ko‘rsatkichi wavelifesciences.com
- foyda va bozor koeffitsiyentlari statistikasi:
WVE - Sof foyda|Kompaniya foydasi prognozi Wave Life Sciences|WVE - P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Wave Life Sciences Ltd|WVE - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Wave Life Sciences Ltd.|WVE - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda Wave Life Sciences|WVE - Bir aksiya uchun sof foyda (EPS TTM)|So'nggi o'n ikki oy davomida yillik hisobda bir aksiya uchun foyda o'sishi wavelifesciences.com|WVE - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foyda o'sishining konsensus prognozi Wave Life Sciences
Kompaniyaning umumiy tahlili:wavelifesciences.com - WVE
Investorlar ushbu koeffitsiyentdan foydalanib, foydaning bitta birligining bozor qiymatini aniqlaydilar hamda aktivning haddan tashqari qimmat baholanganini yoki past baholanish xavfi borligini baholaydilar. Wave Life Sciences (WVE) uchun bozor kapitalizatsiyasi va sof foyda o'rtasidagi bog'liqlik, ya'ni emitentning P/E koeffitsiyenti, bevosita FDA ning RNA dori vositalariga tegishli tartibga soluvchi qarorlariga va GSK bilan B2B hamkorligining samaradorligiga bog'liqdir.
Raqobatdosh kompaniyalar tahlili
Kapitalizatsiyaning foydaga nisbati Tempus AI Inc TEM|Narx-foyda koeffitsiyenti QGEN (Qiagen)|IONS (Ionis Pharmaceuticals, Inc.) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Repligen Corp. RGEN|Avidity Corp - Narxning foydaga nisbati|CRISPR Therapeutics AG - P/E multiplikatori|Biznesning o‘zini qoplash muddati genedx.com WGS|RARE: P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati BEAM (Beam Therapeutics Inc)|SRPT (Sarepta Therapeutics Inc) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Twist Bioscience Corp TWST|Narx-foyda koeffitsiyenti TXG (10x Genomics, Inc.)|NTLA (intelliatx.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Stoke Therapeutics, Inc. STOK|Biznesning o‘zini qoplash muddati BioLife Solutions Inc (BLFS)|Maze Tx - P/E multiplikatori|Sionna Corp (SION) - Narx-foyda koeffitsiyenti|PRME: P/E multiplikatori|TSHA - Biznesning o‘zini qoplash muddati|QURE (uniQure) - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati MeiraGTx Holdings MGTX|Narxning foydaga nisbati Regenxbio (RGNX)|Solid Corp - Narx-foyda multiplikatori|P/E multiplikatori OCGN (Ocugen, Inc.)|PACB - Narx-foyda koeffitsiyenti|Benitec Biopharma - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Design Therapeutics Inc|Rocket Pharmaceuticals Inc (RCKT) - Narxning foydaga nisbati|FDMT - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti LXEO|Narx-foyda koeffitsiyenti Korro Bio, Inc (KRRO)|Narx-foyda koeffitsiyenti EDIT (Editas Medicine)|Narxning foydaga nisbati SLN (Silence Therapeutics PLC)|P/E multiplikatori PRQR (ProQR Therapeutics)|Codexis Inc (CDXS) - Kapitalizatsiyaning foydaga nisbati|Sangamo Therapeutics - P/E multiplikatori|NAUT (Nautilus Biotechnology) - Narx-foyda multiplikatori|Metagenomi (MGX) - Narxning foydaga nisbati|Narx-foyda multiplikatori DTIL|GBIO (Generation Bio Co) - P/E multiplikatori|P/E multiplikatori Boundless Bio Inc|Narx-foyda koeffitsiyenti XCUR (Exicure, Inc.)|Narx-foyda koeffitsiyenti imunon.com IMNN|P/E multiplikatori PHIO (Phio Pharmaceuticals Corp.)|P/E multiplikatori Mustang Bio Inc MBIO|RNAZ: Narx-foyda koeffitsiyenti|BNGO: Narxning foydaga nisbati|APDN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati bluebirdbio.com (BLUE)|Narx-foyda koeffitsiyenti IPA|OMGA: Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Singular Genomics Systems Inc (OMIC)|Narxning foydaga nisbati RGLS (Regulus)|P/E multiplikatori SYRS (Syros Pharmaceuticals)|Biznesning o‘zini qoplash muddati telesisbio.com (TBIO)|TRACON Pharmaceuticals, Inc. - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati UBX
